Managing capivasertib-induced hyperglycemia: a report of 3 cases
Abstract
Phosphoinositide 3-kinase/protein kinase B (AKT) pathway inhibition is an important therapeutic strategy for hormone receptor positive and human epidermal growth factor receptor 2 negative advanced breast cancer. Capivasertib, an oral pan-AKT inhibitor, improves progression-free survival in combination with fulvestrant but is frequently associated with hyperglycemia. Despite this recognized adverse effect, consensus management guidelines are lacking. We describe 3 patients who developed capivasertib-associated hyperglycemia, 2 of whom had severe hyperglycemia with alpelisib therapy, a phosphoinositide 3-kinase inhibitor. Hyperglycemia developed early and was marked by postprandial excursions. All patients were treated with insulin-sensitizing therapies. Preemptive initiation or intensification of antihyperglycemic therapy before capivasertib exposure attenuated hyperglycemia severity. These cases highlight the insulin-resistant phenotype of AKT inhibitor-associated hyperglycemia and support early metabolic assessment, postprandial glucose monitoring, and preferential use of insulin-sensitizing therapies to minimize treatment interruption.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.